文献速递临床试验与 GCP基础与转化研究

GKT137831治疗1型糖尿病伴持续性白蛋白尿的疗效与安全性:统计分析计划

Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan.
PubMed 文献 · Trials · 2020-06-03

本文介绍了一项研究者发起的随机双盲安慰剂对照多中心2期试验的统计分析计划,该试验评估GKT137831在成人1型糖尿病伴持续性尿白蛋白排泄升高患者中48周的疗效与安全性。主要结局为治疗48周时的尿白蛋白排泄水平,计划遵循临床试验统计分析计划指南以增强透明性和可重复性。

要点

  • GKT137831是NOX1/4选择性抑制剂,可能改善糖尿病肾病。
  • 试验为随机双盲安慰剂对照多中心2期设计,疗程48周。
  • 主要结局为48周时尿白蛋白排泄水平,分析计划预先设定。

核心结论

  • 使用预先设定的统计分析计划旨在减少试验结果报告偏倚。
  • 试验结果预计于2022年发表。

研究设计与样本

  • 研究者发起的双盲随机安慰剂对照多中心2期临床试验。
  • 受试者为成人1型糖尿病伴持续性尿白蛋白排泄升高,疗程48周。
  • 试验在澳大利亚和新西兰招募,预计招募于2020年6月30日结束。
  • 统计分析计划遵循临床试验统计分析计划内容指南。

关键数值与推荐

  • 主要结局指标为治疗48周时测量的尿白蛋白排泄水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The investigational medicinal product GKT137831 is a selective inhibitor of NOX 1 and 4 isoforms of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase family of enzymes, which has the potential to ameliorate diabetic kidney disease. An investigator-initiated, double-blind, randomised, placebo-controlled, multicentre phase 2 clinical trial started recruitment in December 2017, with the aim of evaluating the efficacy and safety of GKT13783, in adults with type 1 diabetes mellitus and persistently elevated urinary albumin excretion over a period of 48 weeks. METHODS/DESIGN: The trial is currently recruiting in Australia and New Zealand, with recruitment expected to end on 30 June 2020. The primary outcome measure of the trial is the urinary albumin excretion level measured at 48 weeks of treatment. This statistical analysis plan presents an update to the published trial protocol and provides a comprehensive description of the statistical methods that will be used for the analysis of the data from this trial. In doing so, we follow the "Guidelines for the content of statistical analysis plans in clinical trials" to support transparency and reproducibility of the trial findings. DISCUSSION: With the use of this prior statistical analysis plan, we aim to minimise bias in the reporting of the findings of this trial, which evaluates the investigational medicinal product GKT137831. The results of the trial are expected to be published in 2022. TRIAL REGISTRATION: ANZCTR registry: ACTRN12617001187336. Registered on 14 July 2017. Universal Trial Number: U1111-1187-2609; Protocol number: T1DGKT137831; Genkyotex trial number: GSN000241.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. De Livera AM, Reutens A, Cooper M, et al. Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan. Trials. 2020. PMID: 32493401. doi:10.1186/s13063-020-04404-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。